GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tifeglipron   Click here for help

GtoPdb Ligand ID: 14437

Synonyms: example 485 [US20250154137]
Compound class: Synthetic organic
Comment: The chemical structure for this compound was obtained from WHO INN proposed list 134 (Feb 2026), in which it is described as a glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA) with antidiabetic potential. The structure and its use are claimed in patents held by Carmot Therapeutics [1]. Carmot is now a Roche subsidiary. There is only one declared GLP-1RA in the development pipeline, CT-996 (RG6652; RO7795081). Although the structure for CT-996 is undisclosed (March 2026) we can hazard a guess that tifeglipron is likely the INN match for CT-996. Roche officially describe CT-996 as a cAMP-biased agonist, with minimal effect on β-arrestin recruitment.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 108.55
Molecular weight 579.6
XLogP 1.79
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@H]1C[C@H](CCN1CC2=NC3=C(C=C(C=C3)C(=O)O)N2C[C@@H]4CCO4)OC5=CC=NC(=N5)COC6=CC=C(C=C6F)F
Isomeric SMILES C[C@H]1C[C@H](CCN1CC2=NC3=C(N2C[C@@H]4CCO4)C=C(C=C3)C(=O)O)OC5=NC(=NC=C5)COC6=C(C=C(C=C6)F)F
InChI InChI=1S/C30H31F2N5O5/c1-18-12-21(42-29-6-9-33-27(35-29)17-41-26-5-3-20(31)14-23(26)32)7-10-36(18)16-28-34-24-4-2-19(30(38)39)13-25(24)37(28)15-22-8-11-40-22/h2-6,9,13-14,18,21-22H,7-8,10-12,15-17H2,1H3,(H,38,39)/t18-,21-,22-/m0/s1
InChI Key RZXAFAARGLMEPW-NYVOZVTQSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
CT-996 has been progressed as a clinical candidate for the treatment of overweight or obesity, and tyep 2 diabetes.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05814107 Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus Phase 1 Interventional Carmot Therapeutics, Inc.
NCT07081958 A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Phase 2 Interventional Hoffmann-La Roche
NCT07112872 A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes Phase 2 Interventional Hoffmann-La Roche